>
Switch to:

ITeos Therapeutics Beneish M-Score

: 0.00 (As of Today)
View and export this data going back to 2020. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for ITeos Therapeutics's Beneish M-Score or its related term are showing as below:

During the past 3 years, the highest Beneish M-Score of ITeos Therapeutics was 0.00. The lowest was 0.00. And the median was 0.00.


ITeos Therapeutics Beneish M-Score Historical Data

The historical data trend for ITeos Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ITeos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20
Beneish M-Score
- - -

ITeos Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, ITeos Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ITeos Therapeutics Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, ITeos Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ITeos Therapeutics's Beneish M-Score falls into.



ITeos Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ITeos Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun21) TTM:Last Year (Jun20) TTM:
Accounts Receivable was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $309.77 Mil.
Total Assets was $318.69 Mil.
Property, Plant and Equipment(Net PPE) was $5.07 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.56 Mil.
Selling, General, & Admin. Expense(SGA) was $32.68 Mil.
Total Current Liabilities was $20.76 Mil.
Long-Term Debt & Capital Lease Obligation was $2.50 Mil.
Net Income was -26.459 + -13.534 + -14.904 + -10.68 = $-65.58 Mil.
Non Operating Income was 0.06 + 0.24 + -0.283 + 0.265 = $0.28 Mil.
Cash Flow from Operations was -18.255 + -14.79 + -5.464 + -10.231 = $-48.74 Mil.
Accounts Receivable was $ Mil.
Revenue was 0 + 0 + 0 + 0 = $ Mil.
Gross Profit was + + + = $ Mil.
Total Current Assets was $ Mil.
Total Assets was $ Mil.
Property, Plant and Equipment(Net PPE) was $ Mil.
Depreciation, Depletion and Amortization(DDA) was $ Mil.
Selling, General, & Admin. Expense(SGA) was $ Mil.
Total Current Liabilities was $ Mil.
Long-Term Debt & Capital Lease Obligation was $ Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Accounts Receivable in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0) / ( / 0)
= /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=( / 0) / (0 / 0)
= /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (309.768 + 5.069) / 318.685) / (1 - ( + 1.251) / )
=0.01207462 /
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.554 / (0.554 + 1.251)) / (0.561 / (0.561 + 5.069))
= / 0.09964476
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(32.675 / 0) / ( / 0)
= /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.501 + 20.763) / 318.685) / (( + ) / )
=0.07299998 /
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-65.577 - 0.282 - -48.74) / 318.685
=-0.0537

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


ITeos Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ITeos Therapeutics Business Description

ITeos Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2833
Comparable Companies
Traded in Other Exchanges
N/A
Address
139 Main Street, Cambridge, MA, USA, 02142
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Executives
Evnin Luke 10 percent owner THE JOHN HANCOCK TOWER 200 CLARENDON STREET, 54TH STREET BOSTON MA 02116
Mpm Bioventures 2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2018 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2018 (b), L.p. 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Gp Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 Llc 10 percent owner 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2014 Llc 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Bioventures 2014 (b), L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02124
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC 450 KENDALL STREET CAMBRIDGE MA 02142
Oncology Impact Fund (cayman) Management L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Mpm Oncology Impact Management Gp Llc other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Ubs Oncology Impact Fund L.p. other: X* 450 KENDALL STREET CAMBRIDGE MA 02142
Davis Aaron I. director, 10 percent owner 11682 EL CAMINO REAL, SUITE 320 SAN DIEGO CA 92130

ITeos Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)